pharmaphorum

AUGUST 16, 2021

The Oxford-based company had originally hoped to raise $50 million from the series B, and the scale of the financing is further evidence that repurposing psychedelic compounds as potential therapies for neuro-psychiatric disorders is a hot topic in biopharma.

Compounding 135

Compounding 135

pharmaphorum

MARCH 19, 2021

Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases associated with protein misfolding. . The shares began trading on the Nasdaq yesterday under the symbol ‘GANX’, closing at $11.20

95

95

Express Pharma

JANUARY 10, 2024

ADCs continue to be the hot topic in big pharma. J&J is growing its ADC pipeline, which includes the recently announced $100 million upfront investment to license LCB84, LegoChem Biosciences’ Trop2-directed ADC. In 2022, the global ADC market for cancer treatment was valued at $7.5 billion by 2029 at a CAGR of 27%.

98

98

pharmaphorum

APRIL 20, 2022

The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into the clinic, what therapeutic areas could be set to benefit? Ben Hargreaves takes a look at why oncology could be one of the major beneficiaries of a growing pipeline of CRISPR therapeutics.

Chemotherapy 52

Chemotherapy Immunity Immunization Drug Development 52